Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DDW-Japan 2005 Held in Kobe
October 24, 2005
- Dr Derek Gilroy Wins Bayer HC's 10th Int'l Aspirin Award
October 24, 2005
- SURVEY 2 articles
October 17, 2005
- PMDA Monitors ADRs under Anticancer Combination Therapies
October 17, 2005
- New Chuikyo Starts Full Discussions
October 17, 2005
- MEDICAL DEVICE NEWS IN BRIEF
October 17, 2005
- Discord within Gov't on Control of Medical Expenditure
October 17, 2005
- SELF-MEDICATION NEWS IN BRIEF
October 17, 2005
- Japan Is Not Wasting So Many Resources in Healthcare: Dr Fujii
October 17, 2005
- NEW PRODUCTS
October 17, 2005
- Medical Fees Must Be Raised for Better Healthcare: JMA President
October 17, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 17, 2005
- FPMAJ Opposes More Frequent NHI Price Revisions
October 17, 2005
- 1,636 Organ Transplants in Japan Since 1995
October 17, 2005
- Safety Div. to Monitor Drug Information Supply by Companies
October 17, 2005
- JPMA to Revise Its Promotion Code
October 17, 2005
- REGULATORY NEWS IN BRIEF
October 17, 2005
- Takeda to Take the Offensive in Marketing Actos
October 17, 2005
- JGPMA Member Companies Report Overall Declines in Profits
October 17, 2005
- MCHC Created on Oct. 3 with MCC and MPC as Core Members
October 17, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…